Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nooLVL is a patented, non-stimulant dietary supplement ingredient developed by Nutrition21, specifically designed to enhance cognitive performance, focus, and accuracy. It is a unique complex consisting of Bonded Arginine Silicate (Nitrosigine) combined with an additional optimized dose of Inositol. The ingredient functions by significantly increasing nitric oxide levels, which promotes vasodilation and enhances blood flow to the brain, thereby improving the delivery of oxygen and essential nutrients. The inositol component further supports cognitive health by acting as a precursor for secondary messengers in neurotransmitter signaling pathways involved in learning and memory. Originally targeted at the esports and gaming market, clinical studies have demonstrated that nooLVL can improve focus, concentration, visual attention, and reaction time within as little as 15 minutes of consumption without adversely affecting heart rate or blood pressure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nooLVL.